In summary, miR-33b acts as a tumor suppressor, inhibiting oncogenesis and targeting ovarian cancer lipid metabolism by downregulating TAK1/FASN/CPT1A/NF-κB signaling. The gene discussed is CPT1A; the disease is ovarian carcinoma.